Outcomes of patients receiving salvage therapy after failure of AI, azacitidine, or decitabine
| . | After AI . | After azacitidine . | After decitabine . | P . |
|---|---|---|---|---|
| Total patients, n (%) | 91 (53%) | 35 (20%) | 46 (27%) | |
| Outcome, n (%) | ||||
| No response | 54 (59%) | 27 (77%) | 36 (78% | .001 |
| Early death (< 8 wk) | 37 (41%) | 7 (20%) | 6 (13%) | |
| Median postfailure survival, mo | 1.1 | 0.9 | 3.1 | .048 |
| 1-y | 8% | 10% | 21% | |
| 2-y | 6% | 3% | 8% | |
| . | After AI . | After azacitidine . | After decitabine . | P . |
|---|---|---|---|---|
| Total patients, n (%) | 91 (53%) | 35 (20%) | 46 (27%) | |
| Outcome, n (%) | ||||
| No response | 54 (59%) | 27 (77%) | 36 (78% | .001 |
| Early death (< 8 wk) | 37 (41%) | 7 (20%) | 6 (13%) | |
| Median postfailure survival, mo | 1.1 | 0.9 | 3.1 | .048 |
| 1-y | 8% | 10% | 21% | |
| 2-y | 6% | 3% | 8% | |